Humasis Co. Ltd Total Liabilities

Latest as of September 2025: ₩90.75 Billion KRW ≈ $61.50 Million USD

Humasis Co. Ltd total liabilities. Based on the latest financial reports, Humasis Co. Ltd (205470) has total liabilities worth ₩90.75 Billion KRW (≈ $61.50 Million USD) as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check Humasis Co. Ltd (205470) liquid assets ratio to evaluate the company's liquid asset resilience ratio.

Total Liabilities of Humasis Co. Ltd (2014–2024)

Total liabilities of Humasis Co. Ltd from 2014 to 2024. This chart illustrates how Humasis Co. Ltd's total liabilities have evolved over time, based on quarterly financial data.

Humasis Co. Ltd Competitors by Total Liabilities

The table below lists competitors of Humasis Co. Ltd ranked by their total liabilities.

Company Country Total Liabilities
Terra Santa Propriedades Agrícolas S.A.
SA:LAND3
Brazil R$283.99 Million
KYE Systems Corp
TW:2365
Taiwan NT$506.32 Million
Iris Acquisition Corp II
NYSE:IRAB
USA $7.43 Million
Metro Mining Limited
F:6ME
Germany €174.50 Million
Soechi Lines Tbk
JK:SOCI
Indonesia Rp224.96 Million
Hong Leong Capital Bhd
KLSE:5274
Malaysia RM3.85 Billion
Frauenthal Holding AG
VI:FKA
Austria €204.29 Million
Ascom Holding AG
SW:ASCN
Switzerland CHF121.80 Million

Liability Composition Analysis (2014–2024)

This chart breaks down Humasis Co. Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see how large is Humasis Co. Ltd's balance sheet.

Liquidity & Leverage Metrics

Humasis Co. Ltd Total Liabilities Ratios Explained

Humasis Co. Ltd total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.

Metric Value Description
Current Ratio 2.49 Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio N/A More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio N/A Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity 0.41 Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets 0.27 Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how Humasis Co. Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for Humasis Co. Ltd (2014–2024)

The table below shows the annual total liabilities of Humasis Co. Ltd from 2014 to 2024.

Year Total Liabilities Change
2024-12-31 ₩102.65 Billion
≈ $69.57 Million
+71.14%
2023-12-31 ₩59.98 Billion
≈ $40.65 Million
-50.35%
2022-12-31 ₩120.80 Billion
≈ $81.86 Million
-12.91%
2021-12-31 ₩138.71 Billion
≈ $94.00 Million
+611.03%
2020-12-31 ₩19.51 Billion
≈ $13.22 Million
-8.17%
2019-12-31 ₩21.24 Billion
≈ $14.40 Million
+16.93%
2018-12-31 ₩18.17 Billion
≈ $12.31 Million
+42.74%
2017-12-31 ₩12.73 Billion
≈ $8.63 Million
+906.96%
2016-12-31 ₩1.26 Billion
≈ $856.63K
-70.13%
2015-12-31 ₩4.23 Billion
≈ $2.87 Million
+1.78%
2014-12-31 ₩4.16 Billion
≈ $2.82 Million
--

About Humasis Co. Ltd

KQ:205470 Korea Medical Devices
Market Cap
$172.92 Million
₩255.16 Billion KRW
Market Cap Rank
#16906 Global
#646 in Korea
Share Price
₩2255.00
Change (1 day)
-2.80%
52-Week Range
₩682.00 - ₩4265.00
All Time High
₩8520.77
About

Humasis Co. Ltd. manufactures and sells pharmaceuticals and medical devices in South Korea and internationally. It offers immunodiagnostic kits, such as quantitative and qualitative tests, cardiac and cancer markers, infectious diseases, hormones, and women's health. The company also provides bio-material products, such as COVID-19 nucleocapsid protein, human immunodeficiency virus surface protei… Read more